Proposed Anti-Seizure Medication Combinations With Rufinamide in the Treatment of Lennox-Gastaut Syndrome: Narrative Review and Expert Opinion

First described in the mid-20th century, Lennox-Gastaut syndrome (LGS) is a severe, chronic, and complex form of epilepsy with symptoms including multiple seizure types, interictal generalized slow (≤2.5 Hz) spike-and-wave activity on electroencephalography (EEG), and impaired cognition [1–3]. Onset occurs typically in early childhood, most often between the ages of 3 and 5 years, and persists into adolescence and adulthood [2,4]. Many different etiologies can lead to LGS, including cerebral anomalies, perinatal cerebral anoxia or asphyxia, tuberous sclerosis, acute encephalitis, and head injury, and may involve pre-, peri-, or post-natal factors [1,5].

0